Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

755 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Perez I, Gatell JM; ATADAR Study Group. Martinez E, et al. Among authors: ferrer e. HIV Med. 2014 Jul;15(6):330-8. doi: 10.1111/hiv.12121. Epub 2014 Jan 12. HIV Med. 2014. PMID: 24417772 Free article. Clinical Trial.
Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy).
Casado A, Badia X, Consiglio E, Ferrer E, González A, Pedrol E, Gatell JM, Azuaje C, Llibre JM, Aranda M, Barrufet P, Martínez-Lacasa J, Podzamczer D; COMBINE Study Team. Casado A, et al. Among authors: ferrer e. HIV Clin Trials. 2004 May-Jun;5(3):132-9. doi: 10.1310/EACX-1RFX-41R5-VH45. HIV Clin Trials. 2004. PMID: 15248137 Clinical Trial.
Elvitegravir concentrations in seminal plasma in HIV-1-infected men.
Imaz A, Niubó J, Kashuba AD, Ferrer E, Sykes C, Rozas N, Acerete L, Vila A, Podzamczer D. Imaz A, et al. Among authors: ferrer e. HIV Med. 2017 Mar;18(3):225-230. doi: 10.1111/hiv.12417. Epub 2016 Aug 1. HIV Med. 2017. PMID: 27477062 Free article. Clinical Trial.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Tiraboschi JM, Muñoz-Moreno JA, Puertas MC, Alonso-Villaverde C, Prats A, Ferrer E, Rozas N, Maso M, Ouchi D, Martinez-Picado J, Podzamczer D. Tiraboschi JM, et al. Among authors: ferrer e. HIV Med. 2015 Jul;16(6):388-92. doi: 10.1111/hiv.12243. Epub 2015 Feb 27. HIV Med. 2015. PMID: 25721471 Free article.
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM. García F, et al. Among authors: ferrer e. J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35. doi: 10.1097/00042560-200009010-00004. J Acquir Immune Defic Syndr. 2000. PMID: 11064501 Clinical Trial.
HIV-1 infected patients older than 50 years. PISCIS cohort study.
Navarro G, Nogueras MM, Segura F, Casabona J, Miro JM, Murillas J, Tural C, Ferrer E, Jaén A, Force L, Vilaró J, García I, Masabeu A, Altés J, Esteve A, Sued O, Riera M, Clotet B, Podzamczer D, Gatell JM; PISCIS Study Group. Navarro G, et al. Among authors: ferrer e. J Infect. 2008 Jul;57(1):64-71. doi: 10.1016/j.jinf.2008.05.003. Epub 2008 Jun 24. J Infect. 2008. PMID: 18572247
Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort.
Manzardo C, Esteve A, Ortega N, Podzamczer D, Murillas J, Segura F, Force L, Tural C, Vilaró J, Masabeu A, Garcia I, Guadarrama M, Ferrer E, Riera M, Navarro G, Clotet B, Gatell JM, Casabona J, Miró JM; PISCIS Investigators. Manzardo C, et al. Among authors: ferrer e. Clin Microbiol Infect. 2013 Jul;19(7):646-53. doi: 10.1111/j.1469-0691.2012.03991.x. Epub 2012 Sep 12. Clin Microbiol Infect. 2013. PMID: 22967234 Free article.
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
Podzamczer D, Miró JM, Ferrer E, Gatell JM, Ramón JM, Ribera E, Sirera G, Cruceta A, Knobel H, Domingo P, Polo R, Leyes M, Cosin J, Fariñas MC, Arrizabalaga J, Martínez-Lacasa J, Gudiol F. Podzamczer D, et al. Among authors: ferrer e. Eur J Clin Microbiol Infect Dis. 2000 Feb;19(2):89-95. doi: 10.1007/s100960050436. Eur J Clin Microbiol Infect Dis. 2000. PMID: 10746493 Clinical Trial.
755 results